- Report
- October 2024
- 194 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- March 2025
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- January 2025
- 250 Pages
Global
From €4771EUR$4,999USD£3,997GBP
- Report
- July 2023
- 115 Pages
Global
From €3674EUR$3,850USD£3,079GBP
- Report
- March 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- April 2023
- 117 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- April 2023
- 110 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- October 2024
- 95 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2024
- 81 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- May 2023
- 73 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP

Scopolamine is a drug used to treat a variety of conditions related to the central nervous system. It is a muscarinic antagonist, meaning it blocks the action of the neurotransmitter acetylcholine. It is used to treat motion sickness, nausea, and vomiting, as well as to reduce the symptoms of Parkinson's disease. It is also used to treat irritable bowel syndrome and to reduce the symptoms of opioid withdrawal. Scopolamine is available in both oral and transdermal forms.
Scopolamine is a widely used drug in the central nervous system drug market. It is used to treat a variety of conditions, and its availability in both oral and transdermal forms makes it a popular choice for many patients. It is also relatively inexpensive, making it an attractive option for those with limited budgets.
Some companies in the scopolamine market include Novartis, Merck, Pfizer, and Mylan. Show Less Read more